Alvotech (ICE:ALVO)
652.00
-22.00 (-3.26%)
At close: Nov 21, 2025
Alvotech Revenue
Alvotech had revenue of $113.86M USD in the quarter ending September 30, 2025, with 10.56% growth. This brings the company's revenue in the last twelve months to $573.35M, up 45.55% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$573.35M
Revenue Growth
+45.55%
P/S Ratio
2.95
Revenue / Employee
$566.55K
Employees
1,012
Market Cap
205.61B ISK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 491.98M | 398.60M | 426.84% |
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Marel | 250.20B |
| Hagar | 177.12B |
| Festi | 147.75B |
| Íslandsbanki | 62.96B |
| Arion banki | 61.68B |
| Brim hf. | 58.07B |
| Hampiðjan | 47.38B |
| Sildarvinnslan Hf. | 43.52B |
Alvotech News
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO - PRNewsWire
- 2 days ago - Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 2 days ago - Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 3 days ago - ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
- 3 days ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - GlobeNewsWire
- 8 days ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - GlobeNewsWire
- 9 days ago - Alvotech (ALVO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - ALVO ALERT: Levi & Korsinsky Investigates Alvotech for Possible Securities Fraud Violations - Newsfile Corp